Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 18;32(4):238.
doi: 10.3390/curroncol32040238.

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

Andrée-Anne Pelland  1   2 , Mathilde Dumas  3 , Émilie Lemieux-Blanchard  4 , Richard LeBlanc  3 , Julie Côté  2 , Jean-Samuel Boudreault  5 , Dominic Duquette  2 , Rayan Kaedbey  6 , Marc Lalancette  2 , Frédéric Larose  7 , Anna Nikonova  8 , Michel Pavic  9 , April Shamy  6 , Jean Roy  3 , Michael Sebag  8 , Sabrina Trudel  10 , Jean-Sébastien Claveau  3
Affiliations
Review

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

Andrée-Anne Pelland et al. Curr Oncol. .

Abstract

In the past few years, a new promising therapy, called bispecific T-cell engager (TCE), has been developed and is now available in many countries for patients with relapsed or refractory multiple myeloma. T-cell engagers are associated with sustained efficacy and progression-free survival benefits in patients with heavily treated myeloma. However, complications such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections complicate their administration, particularly in remote centers. This review discusses the key requirements for delivering TCEs therapies, focusing on outpatient delivery. We also outline the primary acute and chronic complications of TCE therapy and their management.

Keywords: bispecific antibodies; multiple myeloma; targeted immunotherapy; toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Key requirements for outpatient delivery of TCEs.
See this image and copyright information in PMC

References

    1. Ferlay J.E.M., Lam F., Laversanne M., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. Global Cancer Observatory: Cancer Today. [(accessed on 29 March 2025)]. Available online: https://gco.iarc.who.int/today.
    1. Gandhi U.H., Cornell R.F., Lakshman A., Gahvari Z.J., McGehee E., Jagosky M.H., Gupta R., Varnado W., Fiala M.A., Chhabra S., et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–2275. doi: 10.1038/s41375-019-0435-7. - DOI - PMC - PubMed
    1. Mateos M.-V., Weisel K., De Stefano V., Goldschmidt H., Delforge M., Mohty M., Cavo M., Vij R., Lindsey-Hill J., Dytfeld D., et al. LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36:1371–1376. doi: 10.1038/s41375-022-01531-2. - DOI - PMC - PubMed
    1. Visram A., De La Torre A., White D., Kardjadj M., Masih-Khan E., Chu M.P., Jimenez-Zepeda V.H., McCurdy A., Leblanc R., Song K., et al. Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 2022;140:4287–4289. doi: 10.1182/blood-2022-168843. - DOI - PMC - PubMed
    1. Hosny M., Verkleij C.P.M., Van Der Schans J., Frerichs K.A., Mutis T., Zweegman S., Van De Donk N.W.C.J. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. J. Clin. Med. 2021;10:4593. doi: 10.3390/jcm10194593. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources